Incidence, prevalence, and outcome of moderate to severe neurotrophic keratopathy in a German tertiary referral center from 2013 to 2017.


Journal

Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
ISSN: 1435-702X
Titre abrégé: Graefes Arch Clin Exp Ophthalmol
Pays: Germany
ID NLM: 8205248

Informations de publication

Date de publication:
Jun 2022
Historique:
received: 28 05 2021
accepted: 22 12 2021
revised: 22 11 2021
pubmed: 7 1 2022
medline: 6 5 2022
entrez: 6 1 2022
Statut: ppublish

Résumé

Neurotrophic keratopathy (NK) is an orphan disease, with an estimated prevalence of 1-5/10,000. No data regarding the incidence exists. The primary aim was to evaluate incidence and prevalence of NK at a tertiary referral center in Germany, and the secondary aim was to analyze demographic parameters, etiology, and clinical features and therapeutic outcomes. All patients treated for NK with serum eye drops (SED), amnionic membrane transplantation (AMT), or penetrating keratoplasty (PK) in 2013-2017 were identified. Age, sex, etiology of NK, visual acuity, disease stage, treatment, and visual acuity were analyzed. Incidence and prevalence of NK in our hospital and the overall population of the city were calculated. In 63 eyes of 60 patients (56.7% male; 68 ± 16 years), the most common underlying diseases were herpetic infections (23.8%), neurological causes (19%), and diabetes mellitus (14.3%). The annual incidence of NK in our tertiary referral center ranges between 5/10,000 and 3/10,000, the prevalence between 9/10,00 and 22/10,000. In all patients treated with corneal ulcers, the prevalence was up to 27% (2706/10,000). The incidence in the overall population is estimated at 0.1-0.3/10,000, the prevalence at 0.2-0.5/10,000 to 0.5/10,000. Based on our assessment, the prevalence of NK in the overall population is lower than estimated before. However, in patients with corneal ulcers, the percentage of NK is comparably high. The disease may still be underdiagnosed due to the variety of underlying disorders and unknown comorbidities. Thus, in cases of therapy-refractive superficial keratopathy or ulcerations, NK should be considered more frequently.

Sections du résumé

BACKGROUND BACKGROUND
Neurotrophic keratopathy (NK) is an orphan disease, with an estimated prevalence of 1-5/10,000. No data regarding the incidence exists. The primary aim was to evaluate incidence and prevalence of NK at a tertiary referral center in Germany, and the secondary aim was to analyze demographic parameters, etiology, and clinical features and therapeutic outcomes.
METHODS AND MATERIAL METHODS
All patients treated for NK with serum eye drops (SED), amnionic membrane transplantation (AMT), or penetrating keratoplasty (PK) in 2013-2017 were identified. Age, sex, etiology of NK, visual acuity, disease stage, treatment, and visual acuity were analyzed. Incidence and prevalence of NK in our hospital and the overall population of the city were calculated.
RESULTS RESULTS
In 63 eyes of 60 patients (56.7% male; 68 ± 16 years), the most common underlying diseases were herpetic infections (23.8%), neurological causes (19%), and diabetes mellitus (14.3%). The annual incidence of NK in our tertiary referral center ranges between 5/10,000 and 3/10,000, the prevalence between 9/10,00 and 22/10,000. In all patients treated with corneal ulcers, the prevalence was up to 27% (2706/10,000). The incidence in the overall population is estimated at 0.1-0.3/10,000, the prevalence at 0.2-0.5/10,000 to 0.5/10,000.
CONCLUSION CONCLUSIONS
Based on our assessment, the prevalence of NK in the overall population is lower than estimated before. However, in patients with corneal ulcers, the percentage of NK is comparably high. The disease may still be underdiagnosed due to the variety of underlying disorders and unknown comorbidities. Thus, in cases of therapy-refractive superficial keratopathy or ulcerations, NK should be considered more frequently.

Identifiants

pubmed: 34989864
doi: 10.1007/s00417-021-05535-z
pii: 10.1007/s00417-021-05535-z
pmc: PMC9061695
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1961-1973

Informations de copyright

© 2022. The Author(s).

Références

Ophthalmology. 2005 May;112(5):888-95
pubmed: 15878072
Ann Transplant. 2018 Mar 06;23:160-165
pubmed: 29507278
Cornea. 2005 Aug;24(6):654-60
pubmed: 16015082
Graefes Arch Clin Exp Ophthalmol. 2006 Oct;244(10):1345-9
pubmed: 16544115
Surv Ophthalmol. 2004 Jan-Feb;49(1):51-77
pubmed: 14711440
Ophthalmologe. 2007 Dec;104(12):1075-9
pubmed: 18030475
Int Ophthalmol. 2018 Jun;38(3):1193-1204
pubmed: 28620707
Br J Ophthalmol. 2004 Nov;88(11):1467-74
pubmed: 15489495
Ophthalmology. 2007 Sep;114(9):1637-42
pubmed: 17382396
Br J Ophthalmol. 2001 Oct;85(10):1188-97
pubmed: 11567963
Ophthalmology. 2018 Sep;125(9):1468-1471
pubmed: 29653861
Ophthalmology. 2004 Jun;111(6):1115-20
pubmed: 15177961
Br J Ophthalmol. 2000 Aug;84(8):826-33
pubmed: 10906085
Ophthalmologe. 2020 Mar;117(3):248-252
pubmed: 31667546
Ophthalmologe. 2019 Aug;116(8):797-810
pubmed: 31372724
Ocul Surf. 2020 Apr;18(2):231-236
pubmed: 31759182
Cornea. 2015 Nov;34 Suppl 11:S121-7
pubmed: 26448169
Clin Ophthalmol. 2014 Mar 19;8:571-9
pubmed: 24672223
Sci Rep. 2020 Apr 30;10(1):7388
pubmed: 32355281
Semin Ophthalmol. 2014 May;29(3):119-26
pubmed: 23758337
Cornea. 2015 Mar;34(3):303-7
pubmed: 25625360
Ophthalmologe. 2005 Jan;102(1):7-14
pubmed: 15538584
J Patient Rep Outcomes. 2020 May 4;4(1):30
pubmed: 32367451
Ophthalmology. 2018 Sep;125(9):1332-1343
pubmed: 29653858
Eye Contact Lens. 2015 Sep;41(5):314-7
pubmed: 25828513
Ophthalmology. 2020 Jan;127(1):14-26
pubmed: 31585826
Dtsch Arztebl Int. 2011 Apr;108(14):243-8
pubmed: 21547164
Prog Retin Eye Res. 2018 Sep;66:107-131
pubmed: 29698813
Exp Eye Res. 2003 May;76(5):521-42
pubmed: 12697417
Ophthalmologe. 2019 Feb;116(2):127-137
pubmed: 30707284
Ocul Surf. 2019 Oct;17(4):619-623
pubmed: 31526824
Eye (Lond). 2006 Jul;20(7):837-9
pubmed: 16215544
Ophthalmology. 2000 Jul;107(7):1347-51; discussion 1351-2
pubmed: 10889110

Auteurs

Mathias Roth (M)

Department of Ophthalmology, Heinrich-Heine University Duesseldorf, Moorenstr. 5, 40225, Duesseldorf, Germany. mathias.roth@med.uni-duesseldorf.de.

Sebastian Dierse (S)

Department of Ophthalmology, Heinrich-Heine University Duesseldorf, Moorenstr. 5, 40225, Duesseldorf, Germany.

Jan Alder (J)

Department of Ophthalmology, Heinrich-Heine University Duesseldorf, Moorenstr. 5, 40225, Duesseldorf, Germany.

Christoph Holtmann (C)

Department of Ophthalmology, Heinrich-Heine University Duesseldorf, Moorenstr. 5, 40225, Duesseldorf, Germany.

Gerd Geerling (G)

Department of Ophthalmology, Heinrich-Heine University Duesseldorf, Moorenstr. 5, 40225, Duesseldorf, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH